Biogen’s Opt-In On Roche’s CD20 Drugs Is Gift That Keeps On Giving

Royalties From Blockbuster Portfolio Amount To Billions

 
• By Andrew McConaghie
Biogen
Biogen is looking for ways to prop up its income as Aduhelm fails to deliver • Source: Alamy

More from Business

More from Scrip